Economic Impact of GLP-1

GLP-1 drugs are poised to revolutionize the economy by addressing the staggering $1.7 trillion cost associated with obesity-related illnesses in the U.S. These medications not only suppress appetite but also tackle cravings, potentially shifting societal norms around food and health. With 70% of Americans classified as overweight or obese, the implications of this technology extend far beyond individual health, challenging the romanticization of unhealthy lifestyles and reshaping our economic landscape.